Cullinan Therapeutics (CGEM) Assets (2020 - 2026)

Cullinan Therapeutics' Assets history runs 7 years deep, the most recent figure standing at $403.0 million for Q1 2026.

• On a quarterly basis, Assets fell 30.48% year-over-year to $403.0 million in Q1 2026; TTM through Mar 2026 was $403.0 million, a 30.48% decrease from a year earlier, with the FY2025 full-year figure at $448.4 million, down 27.89% from the prior year.
• Assets declined to $403.0 million in Q1 2026 per CGEM's latest filing, from $448.4 million in the prior quarter.
• Across five years, Assets topped out at $681.2 million in Q2 2024 and bottomed at $403.0 million in Q1 2026.
• The 5-year median for Assets is $520.3 million (2025), against an average of $537.7 million.
• Across the five-year window, Assets soared 43.69% in 2022 and slumped 30.48% in 2026, its largest moves.
• Year by year, Assets stood at $561.1 million in 2022, then decreased by 13.71% to $484.2 million in 2023, then grew by 28.43% to $621.8 million in 2024, then dropped by 27.89% to $448.4 million in 2025, then decreased by 10.12% to $403.0 million in 2026.
• Per Business Quant, the three latest CGEM Assets figures stand at $403.0 million (Q1 2026), $448.4 million (Q4 2025), and $484.1 million (Q3 2025).